Open-Label, Comparative, Randomized Study of Efficacy and Safety of Exemptia (INN: adalimumab), Solution for Subcutaneous Injection and HumiraA, Solution for Subcutaneous Injection in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Therapy
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Rus Biopharm
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 13 Dec 2017 New trial record